<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Asthma in Children - Part 2: Pharmacological Management</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="asthma-introduction-and-diagnosis.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 50%;"></div>
                        </div>
                       <span class="progress-text">Part 2 of 4</span>
                    </div>
                    <a href="asthma-exacerbation-management.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Asthma in Children, Part 2: Pharmacological Management</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">

                <!-- START: treating-asthma-goals -->
                <section id="treating-asthma-goals" class="content-section" aria-labelledby="section-heading-25">
                    <h2 id="section-heading-25" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Treating Asthma to Control Symptoms and Minimize Risk</span>
                    </h2>
                    <div class="content-card">
                         <h3 class="subsection-heading">Goals of Asthma Management</h3>
                         <p>The long-term goals of asthma management are:</p>
                         <ol>
                            <li><strong>Symptom control:</strong> to achieve good control of symptoms and maintain normal activity levels</li>
                            <li><strong>Risk reduction:</strong> to minimize future risk of exacerbations, fixed airflow limitation and medication side-effects</li>
                         </ol>
                         <p>Achieving these goals requires a partnership between patient and their health care providers.</p>
                         <ul>
                            <li>Ask the patient about their own goals regarding their asthma</li>
                            <li>Good communication strategies are essential</li>
                            <li>Consider the health care system, medication availability, cultural and personal preferences and health literacy</li>
                         </ul>
                    </div>
                </section>
                <!-- END: treating-asthma-goals -->

                <!-- START: symptoms-and-diagnosis-recap -->
                <section id="symptoms-and-diagnosis-recap" class="content-section" aria-labelledby="section-heading-26">
                    <h2 id="section-heading-26" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Symptoms and Diagnosis (Recap)</span>
                    </h2>
                    <div class="content-card">
                        <p>The presence of multiple key indicators increases the probability of asthma, but spirometry is needed to establish a diagnosis.</p>
                        <p><strong>Wheezing</strong>-NB: A lack of wheezing and a normal chest examination do not exclude asthma.</p>
                        <p>History of any of the following:</p>
                        <ul>
                            <li>Cough (worse particularly at night)</li>
                            <li>Recurrent wheeze</li>
                            <li>Recurrent difficulty in breathing</li>
                            <li>Recurrent chest tightness</li>
                        </ul>
                        <p>Symptoms occur or worsen in the presence of:</p>
                        <ul>
                            <li>Exercise</li>
                            <li>Viral infection</li>
                            <li>Inhalant allergens (e.g., animals with fur or hair, house-dust mites, mould, pollen)</li>
                            <li>Irritants (tobacco or wood smoke, airborne chemicals)</li>
                            <li>Changes in weather</li>
                            <li>Strong emotional expression (laughing or crying hard)</li>
                            <li>Stress</li>
                            <li>Menstrual cycles</li>
                        </ul>
                        <p>Symptoms occur or worsen at night, awakening the patient.</p>
                    </div>
                </section>
                <!-- END: symptoms-and-diagnosis-recap -->

                <!-- START: triggers -->
                <section id="triggers" class="content-section" aria-labelledby="section-heading-27">
                    <h2 id="section-heading-27" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Triggers</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li><strong>Allergens:</strong> Pollens, animals, moulds</li>
                            <li><strong>Respiratory infections:</strong> Viruses (mostly)</li>
                            <li><strong>Irritants:</strong> Cigarette smoke, odors, occupational exposures, chemicals, ozone, sulphites, sulphur dioxide</li>
                            <li><strong>Drugs (rare in children):</strong> ASA, NSAIDS, ACE-I, beta blockers</li>
                            <li><strong>Exercise</strong></li>
                            <li><strong>Upper airway inflammation:</strong> Sinusitis, rhinitis</li>
                            <li><strong>Meteorological factors:</strong> Humidity, barometric pressure change, temperature, wind, cold air</li>
                            <li><strong>Gastroesophageal reflux</strong></li>
                        </ul>
                    </div>
                </section>
                <!-- END: triggers -->

                <!-- START: diagnosing-in-child -->
                <section id="diagnosing-in-child" class="content-section" aria-labelledby="section-heading-28">
                    <h2 id="section-heading-28" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Diagnosing Asthma in a Child: History-History-History</span>
                    </h2>
                    <div class="content-card">
                        <p>Suspect asthma if a child has recurrent and/or persistent:</p>
                        <ul>
                            <li>Wheeze, cough, breathlessness</li>
                        </ul>
                        <p>AND are responsive to bronchodilators.</p>
                        <p>Other relevant history supporting asthma:</p>
                        <ul>
                            <li>Personal history of atopy</li>
                            <li>Family history of atopy</li>
                        </ul>
                    </div>
                </section>
                <!-- END: diagnosing-in-child -->

                <!-- START: diagnostic-tests-children -->
                <section id="diagnostic-tests-children" class="content-section" aria-labelledby="section-heading-29">
                    <h2 id="section-heading-29" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Diagnostic Tests in Children</span>
                    </h2>
                    <div class="content-card">
                        <p><strong>Therapeutic trial</strong></p>
                        <ul>
                            <li>Response to bronchodilators (reduction of cough, wheeze)</li>
                            <li>+ response to corticosteroids (5-7 days oral steroids or 2/52 inhaled steroids)</li>
                        </ul>
                        <p><strong>Pulmonary function testing (PFT) - only above 6 years</strong></p>
                        <ul>
                            <li>Peak expiratory flow rate</li>
                            <li>Spirometry</li>
                        </ul>
                        <p><strong>Other tests</strong></p>
                        <ul>
                            <li>Exercise tolerance test (in exercise-induced asthma)</li>
                            <li>Allergen skin prick test</li>
                        </ul>
                    </div>
                </section>
                <!-- END: diagnostic-tests-children -->
                
                <!-- START: pharmacotherapy -->
                <section id="pharmacotherapy" class="content-section" aria-labelledby="section-heading-30">
                    <h2 id="section-heading-30" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Pharmacotherapy</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Medications to Treat Asthma Relievers: Quick Relief</h3>
                        <ul>
                            <li>Taken to relieve symptoms (Rescue medications)</li>
                            <li>For rapid relaxation of airway muscles</li>
                            <li>Quick relief of symptoms (within 2-3 minutes)</li>
                            <li>Used during acute attacks</li>
                            <li>Action lasts 4-6 hrs</li>
                            <li>Not for regular use</li>
                        </ul>

                        <h3 class="subsection-heading">Relievers</h3>
                        <ul>
                            <li><strong>Short acting $\beta_{2}$ agonists:</strong> Salbutamol, Levosalbutamol</li>
                            <li><strong>Anti-cholinergics:</strong> Ipratropium bromide</li>
                            <li><strong>Xanthines:</strong> Theophylline, Adrenaline</li>
                        </ul>
                        
                        <h3 class="subsection-heading">Medications to Treat Asthma: Long-Term Control (Controllers)</h3>
                        <ul>
                            <li>Taken daily over a long period of time</li>
                            <li>Prevent future attacks</li>
                            <li>Long term control of asthma</li>
                            <li>Prevent airway remodelling</li>
                            <li>Used to reduce inflammation, relax airway muscles, and improve symptoms and lung function</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Controller Medication Classes</caption>
                                <thead>
                                    <tr>
                                        <th>Corticosteroids</th>
                                        <th>Anti-leukotrienes</th>
                                        <th>Xanthines</th>
                                        <th>Long acting $\beta_{2}$ agonists</th>
                                        <th>Mast cell stabilisers</th>
                                        <th>Combinations</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Prednisolone, Betamethasone<br>Beclomethasone, Budesonide<br>Fluticasone</td>
                                        <td>Montelukast, Zafirlukast</td>
                                        <td>Theophylline SR</td>
                                        <td>Bambuterol, Salmeterol<br>Formoterol</td>
                                        <td>Sodium cromoglycate</td>
                                        <td>Salmeterol/Fluticasone<br>Formoterol/Budesonide<br>Salbutamol/Beclomethasone</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3 class="subsection-heading">Inhaled Corticosteroids (ICS): Considerations in Children</h3>
                        <ul>
                            <li><strong>Growth:</strong> At low-medium doses, ICS may cause a small reduction in growth (~1 cm) only during the first year, which is non-progressive. Poorly controlled asthma has a greater potential of reducing growth than ICS use.</li>
                            <li><strong>Local side effects (rare in young children):</strong> Thrush, dysphonia - minimize by wiping peri-oral skin and rinsing mouth after inhalation.</li>
                            <li><strong>Bone density:</strong> No effect at low-medium doses.</li>
                        </ul>

                        <h3 class="subsection-heading">Long-acting beta-agonist (LABA)</h3>
                        <ul>
                            <li>LABAs relax airway smooth muscle but have NO anti-inflammatory activity.</li>
                            <li>Add LABA to low or medium-dose ICS as step-up therapy in a poorly controlled child.</li>
                            <li>This provides more benefit than increasing the dose of ICS beyond a medium dose.</li>
                            <li><strong>Potential adverse effects:</strong> Tachycardia, tremor, insomnia. A paradoxical increase in serious asthma exacerbations can occur in some patients due to downregulation of $\beta_{2}$-receptors (less relief from salbutamol!).</li>
                            <li><strong>Bottomline:</strong> Always combine ICS/LABA.</li>
                        </ul>

                        <h3 class="subsection-heading">Leukotriene antagonists</h3>
                        <ul>
                            <li>Used as step-up therapy in addition to ICS.</li>
                            <li>May have an additive benefit when used with an ICS, but the benefit is less favorable compared to adding a LABA.</li>
                            <li>However, in the "real-world", LTRA may be equally effective since many patients prefer oral medications over inhaled ones, leading to increased adherence.</li>
                            <li><strong>Paediatric formulations (Monteleukast):</strong>
                                <ul>
                                    <li>4 mg sachets (sweet granules)</li>
                                    <li>5 mg chewable tab ("sweet")</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: pharmacotherapy -->
                
                <!-- START: other-controller-meds -->
                <section id="other-controller-meds" class="content-section" aria-labelledby="section-heading-31">
                    <h2 id="section-heading-31" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Pharmacologic Therapy - Other Controller Medications</span>
                    </h2>
                    <div class="content-card">
                         <div class="table-container">
                            <table class="content-table">
                               <thead>
                                  <tr>
                                     <th>Controller Medication</th>
                                     <th>Formulation</th>
                                     <th>Child dose</th>
                                  </tr>
                               </thead>
                               <tbody>
                                  <tr>
                                     <td>Leucotriene receptor antagonists (Monteleukast)</td>
                                     <td>4 mg sachets<br>5, 10 mg tablets</td>
                                     <td>Child - 4-5 mg od<br>Adolescent 10 mg od</td>
                                  </tr>
                                  <tr>
                                     <td>Long acting beta2 agonist (Salmeterol, Formoterol)</td>
                                     <td>DPI 50 $\mu$g/blister<br>DPI 12 $\mu$g/blister</td>
                                     <td>1 inhalation bid</td>
                                  </tr>
                                  <tr>
                                     <td>Combination ICS/LABA (e.g., Budesonide/formoterol)</td>
                                     <td>MDI, DPI<br>50, 100, 250/50 $\mu$g<br>50, 125/25 $\mu$g<br>80, 160/4.5 $\mu$g</td>
                                     <td>1 inhalation bid<br>1 puff bid<br>1 inhalation bid</td>
                                  </tr>
                               </tbody>
                            </table>
                         </div>
                    </div>
                </section>
                <!-- END: other-controller-meds -->

                <!-- START: stepwise-management -->
                <section id="stepwise-management" class="content-section" aria-labelledby="section-heading-32">
                    <h2 id="section-heading-32" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Stepwise Management Pharmacotherapy</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-070-1.jpg" alt="GINA stepwise management of asthma. Step 1: As-needed SABA. Step 2: Low dose ICS. Step 3: Low dose ICS/LABA. Step 4: Medium/high dose ICS/LABA. Step 5: Refer for add-on treatment like tiotropium or biologics." class="content-image">
                        </figure>
                        <p><small>*Not for children <12 years<br>**For children 6-11 years, the preferred Step 3 treatment is medium dose ICS<br>#For patients prescribed BDP/formoterol or BUD/ formoterol maintenance and reliever therapy<br>+ Tiotropium by mist inhaler is an add-on treatment for patients $\geq 12$ years with a history of exacerbations</small></p>
                        <h3 class="subsection-heading">Remember to...</h3>
                         <ul>
                            <li>Provide guided self-management education</li>
                            <li>Treat modifiable risk factors and comorbidities</li>
                            <li>Advise about non-pharmacological therapies and strategies</li>
                            <li>Consider stepping up if symptoms, exacerbations or risks are uncontrolled, but check diagnosis, inhaler technique and adherence first</li>
                            <li>Consider stepping down if symptoms have been controlled for 3 months and risk for exacerbations is low. Ceasing ICS is not advised.</li>
                         </ul>
                    </div>
                </section>
                <!-- END: stepwise-management -->
                
                <!-- START: step1 -->
                <section id="step1" class="content-section" aria-labelledby="section-heading-33">
                    <h2 id="section-heading-33" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Step 1 - As-needed Reliever Inhaler</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-072-1.jpg" alt="GINA stepwise management chart with Step 1 highlighted: As-needed SABA." class="content-image">
                        </figure>
                        <p><strong>Preferred option:</strong> as-needed inhaled short-acting beta$_{2}$-agonist (SABA).</p>
                        <p>SABAs are highly effective for relief of asthma symptoms. However, there is insufficient evidence about the safety of treating asthma with SABA alone. This option should be reserved for patients with infrequent symptoms (less than twice a month) of short duration, and with no risk factors for exacerbations.</p>
                        <p><strong>Other options:</strong> Consider adding regular low dose inhaled corticosteroid (ICS) for patients at risk of exacerbations.</p>
                    </div>
                </section>
                <!-- END: step1 -->

                <!-- START: step2 -->
                <section id="step2" class="content-section" aria-labelledby="section-heading-34">
                    <h2 id="section-heading-34" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Step 2 - Low-Dose Controller + As-Needed SABA</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-074-1.jpg" alt="GINA stepwise management chart with Step 2 highlighted: Low dose ICS controller plus as-needed SABA." class="content-image">
                        </figure>
                        <p><strong>Preferred option:</strong> regular low dose ICS with as-needed inhaled SABA.</p>
                        <p>Low dose ICS reduces symptoms and reduces risk of exacerbations and asthma-related hospitalization and death.</p>
                        <p><strong>Other options:</strong></p>
                        <ul>
                            <li><strong>Leukotriene receptor antagonists (LTRA) with as-needed SABA:</strong> Less effective than low dose ICS. May be used for some patients with both asthma and allergic rhinitis, or if patient will not use ICS.</li>
                            <li><strong>Combination low dose ICS/long-acting beta$_{2}$-agonist (LABA) with as-needed SABA:</strong> Reduces symptoms and increases lung function compared with ICS. More expensive, and does not further reduce exacerbations.</li>
                            <li><strong>Intermittent ICS with as-needed SABA for purely seasonal allergic asthma with no interval symptoms:</strong> Start ICS immediately as symptoms commence, and continue for 4 weeks after pollen season ends.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: step2 -->

                <!-- START: step3 -->
                <section id="step3" class="content-section" aria-labelledby="section-heading-35">
                    <h2 id="section-heading-35" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Step 3 - One or Two Controllers + As-Needed Reliever</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-076-1.jpg" alt="GINA stepwise management chart with Step 3 highlighted: Low dose ICS/LABA as controller plus as-needed reliever." class="content-image">
                        </figure>
                        <p><strong>Before considering step-up:</strong> Check inhaler technique and adherence, confirm diagnosis.</p>
                        <p><strong>Adults/adolescents:</strong> preferred options are either combination low dose ICS/LABA maintenance with as-needed SABA, OR combination low dose ICS/formoterol maintenance and reliever regimen*. Adding LABA reduces symptoms and exacerbations and increases FEV$_{1}$, while allowing lower dose of ICS. In at-risk patients, maintenance and reliever regimen significantly reduces exacerbations with similar level of symptom control and lower ICS doses compared with other regimens.</p>
                        <p><strong>Children 6-11 years:</strong> preferred option is medium dose ICS with as-needed SABA.</p>
                        <p><strong>Other options:</strong></p>
                        <ul>
                            <li><strong>Adults/adolescents:</strong> Increase ICS dose or add LTRA or theophylline (less effective than ICS/LABA).</li>
                            <li><strong>Children 6-11 years:</strong> add LABA (similar effect as increasing ICS).</li>
                        </ul>
                    </div>
                </section>
                <!-- END: step3 -->

                <!-- START: step4 -->
                <section id="step4" class="content-section" aria-labelledby="section-heading-36">
                    <h2 id="section-heading-36" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Step 4 - Two or More Controllers + As-Needed Reliever</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-078-1.jpg" alt="GINA stepwise management chart with Step 4 highlighted: Medium or high dose ICS/LABA controller plus as-needed reliever." class="content-image">
                        </figure>
                        <p><strong>Before considering step-up:</strong> Check inhaler technique and adherence.</p>
                        <p><strong>Adults or adolescents:</strong> preferred option is combination low dose ICS/formoterol as maintenance and reliever regimen*, OR combination medium dose ICS/LABA with as-needed SABA.</p>
                        <p><strong>Children 6-11 years:</strong> preferred option is to refer for expert advice.</p>
                        <p><strong>Other options (adults or adolescents):</strong></p>
                        <ul>
                            <li>Tiotropium by mist inhaler may be used as add-on therapy for patients aged $\geq 12$ years with a history of exacerbations.</li>
                            <li>Trial of high dose combination ICS/LABA, but little extra benefit and increased risk of side-effects.</li>
                            <li>Increase dosing frequency (for budesonide-containing inhalers).</li>
                            <li>Add-on LTRA or low dose theophylline.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: step4 -->

                <!-- START: step5 -->
                <section id="step5" class="content-section" aria-labelledby="section-heading-37">
                    <h2 id="section-heading-37" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Step 5 - Higher Level Care and/or Add-On Treatment</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_14_202924806913c28d4c29g-080-1.jpg" alt="GINA stepwise management chart with Step 5 highlighted: Refer for add-on treatment." class="content-image">
                        </figure>
                        <p><strong>Preferred option is referral for specialist investigation and consideration of add-on treatment.</strong></p>
                        <p>If symptoms uncontrolled or exacerbations persist despite Step 4 treatment, check inhaler technique and adherence before referring.</p>
                        <ul>
                            <li>Add-on tiotropium for patients $\geq 12$ years with history of exacerbations.</li>
                            <li>Add-on omalizumab (anti-IgE) for patients with severe allergic asthma.</li>
                            <li>Add-on mepolizumab (anti-IL5) for severe eosinophilic asthma ($\geq 12$ yrs).</li>
                        </ul>
                        <p><strong>Other add-on treatment options at Step 5 include:</strong></p>
                        <ul>
                            <li><strong>Sputum-guided treatment:</strong> this is available in specialized centers; reduces exacerbations and/or corticosteroid dose.</li>
                            <li><strong>Add-on low dose oral corticosteroids ($\leq 7.5$ mg/day prednisone equivalent):</strong> this may benefit some patients, but has significant systemic side-effects. Assess and monitor for osteoporosis.</li>
                        </ul>
                        <p>See ERS/ATS Severe Asthma Guidelines (Chung et al, ERJ 2014) for more detail.</p>
                    </div>
                </section>
                <!-- END: step5 -->
                
                <!-- START: ics-doses-adults -->
                <section id="ics-doses-adults" class="content-section" aria-labelledby="section-heading-38">
                    <h2 id="section-heading-38" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Low, Medium and High Dose Inhaled Corticosteroids (Adults & Adolescents >12 Years)</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Total daily dose (mcg)</caption>
                                <thead>
                                    <tr>
                                        <th>Inhaled corticosteroid</th>
                                        <th>Low</th>
                                        <th>Medium</th>
                                        <th>High</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr><td>Beclometasone dipropionate (CFC)</td><td>200-500</td><td>>500-1000</td><td>>1000</td></tr>
                                    <tr><td>Beclometasone dipropionate (HFA)</td><td>100-200</td><td>>200-400</td><td>>400</td></tr>
                                    <tr><td>Budesonide (DPI)</td><td>200-400</td><td>>400-800</td><td>>800</td></tr>
                                    <tr><td>Ciclesonide (HFA)</td><td>80-160</td><td>>160-320</td><td>>320</td></tr>
                                    <tr><td>Fluticasone furoate (DPI)</td><td>100</td><td>n.a.</td><td>200</td></tr>
                                    <tr><td>Fluticasone propionate (DPI or HFA)</td><td>100-250</td><td>>250-500</td><td>>500</td></tr>
                                    <tr><td>Mometasone furoate</td><td>110-220</td><td>>220-440</td><td>>440</td></tr>
                                    <tr><td>Triamcinolone acetonide</td><td>400-1000</td><td>>1000-2000</td><td>>2000</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <p><small>This is not a table of equivalence, but of estimated clinical comparability. Most of the clinical benefit from ICS is seen at low doses. High doses are arbitrary, but for most ICS are those that, with prolonged use, are associated with an increased risk of systemic side-effects.</small></p>
                    </div>
                </section>
                <!-- END: ics-doses-adults -->

                <!-- START: ics-doses-children -->
                <section id="ics-doses-children" class="content-section" aria-labelledby="section-heading-39">
                    <h2 id="section-heading-39" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Low, Medium and High Dose Inhaled Corticosteroids (Children 6-11 Years)</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Total daily dose (mcg)</caption>
                                <thead>
                                    <tr>
                                        <th>Inhaled corticosteroid</th>
                                        <th>Low</th>
                                        <th>Medium</th>
                                        <th>High</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr><td>Beclometasone dipropionate (CFC)</td><td>100-200</td><td>>200-400</td><td>>400</td></tr>
                                    <tr><td>Beclometasone dipropionate (HFA)</td><td>50-100</td><td>>100-200</td><td>>200</td></tr>
                                    <tr><td>Budesonide (DPI)</td><td>100-200</td><td>>200-400</td><td>>400</td></tr>
                                    <tr><td>Budesonide (nebules)</td><td>250-500</td><td>>500-1000</td><td>>1000</td></tr>
                                    <tr><td>Ciclesonide (HFA)</td><td>80</td><td>>80-160</td><td>>160</td></tr>
                                    <tr><td>Fluticasone furoate (DPI)</td><td>n.a.</td><td>n.a.</td><td>n.a.</td></tr>
                                    <tr><td>Fluticasone propionate (DPI)</td><td>100-200</td><td>>200-400</td><td>>400</td></tr>
                                    <tr><td>Fluticasone propionate (HFA)</td><td>100-200</td><td>>200-500</td><td>>500</td></tr>
                                    <tr><td>Mometasone furoate</td><td>110</td><td>$\geq 220$ - <440</td><td>$\geq 440$</td></tr>
                                    <tr><td>Triamcinolone acetonide</td><td>400-800</td><td>>800-1200</td><td>>1200</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <p><small>This is not a table of equivalence, but of estimated clinical comparability. Most of the clinical benefit from ICS is seen at low doses. High doses are arbitrary, but for most ICS are those that, with prolonged use, are associated with an increased risk of systemic side-effects.</small></p>
                    </div>
                </section>
                <!-- END: ics-doses-children -->

                <!-- START: reviewing-response -->
                <section id="reviewing-response" class="content-section" aria-labelledby="section-heading-40">
                    <h2 id="section-heading-40" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Reviewing Response and Adjusting Treatment</span>
                    </h2>
                    <div class="content-card">
                        <div style="display: flex; flex-wrap: wrap; align-items: flex-start; gap: 1rem;">
                            <div style="flex: 1; min-width: 300px;">
                                 <p><strong>How often should asthma be reviewed?</strong></p>
                                 <ul>
                                    <li>1-3 months after treatment started, then every 3-12 months</li>
                                    <li>During pregnancy, every 4-6 weeks</li>
                                    <li>After an exacerbation, within 1 week</li>
                                 </ul>
                                 <p><strong>Stepping up asthma treatment</strong></p>
                                 <ul>
                                    <li><strong>Sustained step-up:</strong> for at least 2-3 months if asthma is poorly controlled. Important: first check for common causes (symptoms not due to asthma, incorrect inhaler technique, poor adherence).</li>
                                    <li><strong>Short-term step-up:</strong> for 1-2 weeks, e.g. with a viral infection or allergen. May be initiated by the patient with a written asthma action plan.</li>
                                    <li><strong>Day-to-day adjustment:</strong> For patients prescribed low-dose ICS/formoterol maintenance and reliever regimen*.</li>
                                 </ul>
                                 <p><strong>Stepping down asthma treatment</strong></p>
                                 <ul>
                                     <li>Consider step-down after good control has been maintained for 3 months.</li>
                                     <li>Find each patient's minimum effective dose that controls both symptoms and exacerbations.</li>
                                 </ul>
                            </div>
                            <figure style="flex: 0 1 300px; margin: auto;">
                                <img src="../assets/images/2025_06_14_202924806913c28d4c29g-084-1.jpg" alt="A circular diagram representing the continuous cycle of asthma management: Assess, Adjust Treatment, and Review Response." class="content-image">
                            </figure>
                        </div>
                    </div>
                </section>
                <!-- END: reviewing-response -->
                
                <!-- START: stepping-down-principles -->
                <section id="stepping-down-principles" class="content-section" aria-labelledby="section-heading-41">
                    <h2 id="section-heading-41" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">General Principles for Stepping Down Controller Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>The goal is to find the lowest dose that controls symptoms and exacerbations, and minimizes the risk of side-effects.</p>
                        <p><strong>When to consider stepping down:</strong></p>
                        <ul>
                            <li>When symptoms have been well controlled and lung function stable for $\geq 3$ months.</li>
                            <li>No respiratory infection, patient not travelling, not pregnant.</li>
                        </ul>
                        <p><strong>Prepare for step-down:</strong></p>
                        <ul>
                            <li>Record the level of symptom control and consider risk factors.</li>
                            <li>Make sure the patient has a written asthma action plan.</li>
                            <li>Book a follow-up visit in 1-3 months.</li>
                        </ul>
                        <p><strong>Step down through available formulations:</strong></p>
                        <ul>
                            <li>Stepping down ICS doses by 25-50% at 3-month intervals is feasible and safe for most patients (Hagan et al, Allergy 2014).</li>
                            <li>See GINA 2016 report Box 3-7 for specific step-down options.</li>
                            <li>Stopping ICS is not recommended in adults with asthma because of the risk of exacerbations (Rank et al, JACI 2013).</li>
                        </ul>
                    </div>
                </section>
                <!-- END: stepping-down-principles -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="asthma-introduction-and-diagnosis.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 50%;"></div>
                        </div>
                       <span class="progress-text">Part 2 of 4</span>
                    </div>
                    <a href="asthma-exacerbation-management.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>